India Pharmacovigilance Market

India Pharmacovigilance Market Research Report: Size, Share, Trend Analysis By Service Type (Adverse Event Reporting, Risk Assessment, Data Mining, Pharmacovigilance Consulting), By Deployment Mode (Cloud-Based, On-Premise), By Source (Spontaneous Reporting, Literature Reports, Scheduled Reporting), and By End-user (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations) - Growth Outlook & Industry Forecast 2025 To 2035
ID: MRFR/MED/49696-HCR 200 Pages Nidhi Mandole, Rahul Gotadki Last Updated: September 17, 2026
India Pharmacovigilance Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)8.62%
2024 Market Size$ 314.13 Million
2025 Market Size$ 341.21 Million
2035 Market Size$ 780.04 Million
Key Players
Parexel
Covance
IQVIA
Wuxi AppTec
Syneos Health
Medpace
Trends
  • Technological Advancements
  • Regulatory Compliance
  • Collaboration Among Stakeholders
Opportunities
  • Increased Regulatory Scrutiny
  • Growing Awareness of Patient Safety
  • Expansion of Pharmaceutical Industry
Request Free Sample

India Pharmacovigilance Market Summary

As per Market Research Future analysis, the India pharmacovigilance market Size was estimated at 314.13 $ Million in 2024. The India pharmacovigilance market is projected to grow from 341.21 $ Million in 2025 to 780.04 $ Million by 2035, exhibiting a compound annual growth rate (CAGR) of 8.6% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The India pharmacovigilance market is poised for substantial growth driven by technological advancements and regulatory compliance.

  • Technological advancements are enhancing data collection and analysis in the pharmacovigilance sector.
  • The largest segment in the India pharmacovigilance market is the pharmaceutical industry, while the fastest-growing segment is the biotechnology sector.
  • Collaboration among stakeholders is becoming increasingly vital for effective drug safety monitoring.
  • Rising demand for drug safety monitoring and increased regulatory scrutiny are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 314.13 (USD Million)
2035 Market Size 780.04 (USD Million)
CAGR (2025 - 2035) 8.62%

Major Players

Parexel (US), Covance (US), IQVIA (US), Wuxi AppTec (CN), Syneos Health (US), Medpace (US), PPD (US), Charles River (US)

India Pharmacovigilance Market Drivers

Increased Regulatory Scrutiny

The pharmacovigilance market in India is significantly influenced by heightened regulatory scrutiny. Regulatory bodies, such as the Central Drugs Standard Control Organization (CDSCO), are enforcing stricter guidelines for drug safety and efficacy. This increased oversight compels pharmaceutical companies to invest in comprehensive pharmacovigilance systems to monitor and report ADRs effectively. As a result, the market is witnessing a surge in demand for advanced pharmacovigilance solutions. The regulatory landscape is evolving, with expectations for real-time data reporting and risk management strategies. This trend indicates that companies must adapt to these changes to maintain compliance and ensure patient safety, thereby driving growth in the pharmacovigilance market.

Growing Awareness of Patient Safety

There is a notable increase in awareness regarding patient safety among healthcare professionals and the general public in India. This heightened awareness is driving the demand for effective pharmacovigilance practices, as stakeholders recognize the importance of monitoring drug safety. Educational initiatives and campaigns aimed at informing healthcare providers about the significance of ADR reporting are gaining traction. Consequently, this trend is likely to bolster the pharmacovigilance market, as more healthcare professionals engage in reporting and monitoring activities. The emphasis on patient safety is expected to lead to improved healthcare outcomes and a more robust pharmacovigilance framework in the country.

Expansion of Pharmaceutical Industry

The rapid expansion of the pharmaceutical industry in India is a crucial driver for the pharmacovigilance market. As more pharmaceutical companies establish operations in the country, the need for effective pharmacovigilance systems becomes increasingly apparent. The growth of the industry is accompanied by a rise in the number of new drug approvals, which necessitates comprehensive monitoring of safety profiles. With the Indian pharmaceutical market projected to reach $65 billion by 2024, the demand for pharmacovigilance services is likely to increase correspondingly. This expansion presents opportunities for service providers to offer innovative solutions that cater to the evolving needs of the industry, thereby propelling the pharmacovigilance market forward.

Rising Demand for Drug Safety Monitoring

The increasing focus on drug safety monitoring is a primary driver for the pharmacovigilance market in India. With a growing population and rising healthcare needs, the demand for effective monitoring of adverse drug reactions (ADRs) has surged. The Indian healthcare system is witnessing a shift towards more stringent safety protocols, which necessitates robust pharmacovigilance practices. According to recent estimates, the pharmacovigilance market in India is projected to grow at a CAGR of approximately 15% over the next few years. This growth is driven by the need for pharmaceutical companies to ensure patient safety and comply with regulatory requirements, thereby enhancing the overall quality of healthcare services in the country.

Technological Integration in Pharmacovigilance

The integration of advanced technologies into pharmacovigilance practices is reshaping the market landscape in India. The adoption of artificial intelligence (AI), machine learning, and big data analytics is enhancing the ability to detect and analyze ADRs more efficiently. These technologies enable real-time monitoring and predictive analytics, which are crucial for timely decision-making in drug safety. As pharmaceutical companies increasingly recognize the value of these innovations, the pharmacovigilance market is expected to expand. Reports suggest that the market for AI-driven pharmacovigilance solutions could reach $500 million by 2027, reflecting the growing reliance on technology to improve drug safety outcomes.

Market Segment Insights

By Service Type: Adverse Event Reporting (Largest) vs. Pharmacovigilance Consulting (Fastest-Growing)

The service type segment in the India pharmacovigilance market is primarily dominated by Adverse Event Reporting, which captures the majority share among the various service categories. Risk Assessment follows as a significant contributor, while Data Mining and Pharmacovigilance Consulting play vital roles, albeit with smaller shares. This distribution highlights the critical nature of post-market surveillance services in ensuring drug safety and compliance with regulatory standards. Recent trends indicate that while Adverse Event Reporting remains the cornerstone of pharmacovigilance services, the demand for Pharmacovigilance Consulting is on the rise, making it the fastest-growing service type. Factors such as increased regulatory pressure and a growing focus on patient safety have spurred this growth. Additionally, advancements in technology and data analytics are enhancing the effectiveness of these services, driving their adoption by pharmaceutical companies and healthcare organizations.

Adverse Event Reporting (Dominant) vs. Pharmacovigilance Consulting (Emerging)

Adverse Event Reporting serves as the dominant force in the market, characterized by its extensive processes for collecting and analyzing data related to adverse drug reactions. This service ensures compliance with regulatory requirements, maintaining safety across drug lifecycles. In contrast, Pharmacovigilance Consulting is emerging as an essential service, offering strategic insights and guidance to healthcare stakeholders on best practices and regulatory expectations. Its growth is fueled by the increasing complexity of drug development and the necessity for tailored solutions that address specific challenges within pharmacovigilance. Both segments play complementary roles, with Adverse Event Reporting solidifying market foundations while Consulting addresses evolving demands.

By Deployment Mode: Cloud-Based (Largest) vs. On-Premise (Fastest-Growing)

In the India pharmacovigilance market, the deployment mode segment is primarily composed of Cloud-Based solutions, which dominate the landscape due to their scalability and accessibility. These solutions account for a significant share of the market, driven by increasing demand for agile and efficient pharmacovigilance processes. In contrast, On-Premise deployment is gaining traction as companies seek enhanced security and control over their data, marking it as the fastest-growing segment amidst changing regulatory requirements. The growth trends indicate a shift towards digitalization in the pharmacovigilance processes, with Cloud-Based solutions leading the charge thanks to their ability to support real-time monitoring and data analysis. Meanwhile, On-Premise solutions are appealing to organizations that prioritize data sovereignty and customization, particularly in highly regulated environments. This duality in preferences showcases diverse operational needs within the industry, fostering competitive innovation.

Deployment Mode: Cloud-Based (Dominant) vs. On-Premise (Emerging)

Cloud-Based solutions in the India pharmacovigilance market have established themselves as the dominant approach, offering extensive benefits such as lower initial costs, enhanced collaboration, and ease of updates. These solutions are particularly favored for their flexibility, allowing organizations to adapt rapidly to changing regulatory landscapes and operational demands. On the other hand, On-Premise solutions are positioned as emerging alternatives, catering to businesses that prioritize data security and customization, which are critical in the context of sensitive health data management. As organizations increasingly scrutinize compliance with stringent regulations, the shift towards On-Premise solutions represents a strategic pivot, ensuring that companies can maintain greater control over their pharmacovigilance activities while also meeting their unique operational requirements.

By Source: Spontaneous Reporting (Largest) vs. Literature Reports (Fastest-Growing)

In the India pharmacovigilance market, Spontaneous Reporting holds the largest share among the sources of safety data collection, capturing a significant portion of the overall market. This robust segment relies on the voluntary submission of adverse event findings by healthcare professionals, contributing to an extensive database of safety profiles for various drugs. In contrast, Literature Reports, while smaller in market share, represent a dynamic and fast-evolving segment that is gaining traction with increasing research publication volumes. This dual source approach enhances the comprehensiveness of safety data available to stakeholders. The growth trends in the Source segment are driven by several key factors. With heightened awareness of drug safety concerns, healthcare professionals are more proactive in reporting adverse events, thus bolstering the Spontaneous Reporting segment. Concurrently, the rise in literature publications related to clinical studies and drug efficacy is energizing the Literature Reports segment, making it a significant player in pharmacovigilance. This trend is facilitated by advancements in digital platforms that streamline the monitoring of published literature, expanding the scope for adverse event identification and analysis, resulting in improved patient safety outcomes.

Spontaneous Reporting (Dominant) vs. Literature Reports (Emerging)

Spontaneous Reporting dominates the Source segment in the India pharmacovigilance market, characterized by a robust process where healthcare practitioners voluntarily report adverse drug reactions. This method ensures a diverse range of reports, contributing to a rich database that is crucial for ongoing drug safety evaluation. Conversely, Literature Reports are emerging as a significant source of safety information, especially with the increasing number of published clinical studies. While they currently hold a smaller market share, their growth is fueled by the need for comprehensive safety data. This method enhances the pharmacovigilance framework by providing structured insights from peer-reviewed literature, playing a pivotal role in assessing drug safety and efficacy in real-world settings.

By End User: Pharmaceutical Companies (Largest) vs. Contract Research Organizations (Fastest-Growing)

Pharmaceutical companies hold a significant share in the India pharmacovigilance market, leading the sector with their robust reporting systems and regulatory compliance efforts. They dominate the market due to their extensive drug portfolios and the increasing need for safety monitoring as new drugs are introduced. In contrast, contract research organizations (CROs) are gaining momentum, capitalizing on the demand for outsourced pharmacovigilance services as companies seek cost-effective solutions to manage their compliance requirements. The growth trends for this segment are largely driven by regulatory changes and an increasing focus on patient safety. As more pharmaceutical companies rely on CROs for their expertise, the latter is expected to expand rapidly in the coming years. Furthermore, advancements in technology and data analytics are transforming how both segments operate, enhancing their ability to track drug safety issues efficiently. The interplay between these entities highlights a dynamic environment where innovation and regulatory adaptation are key to success.

Pharmaceutical Companies: Dominant vs. Contract Research Organizations: Emerging

Pharmaceutical companies serve as the bedrock of the India pharmacovigilance market, characterized by their intricate understanding of drug development and safety frameworks. They leverage substantial R&D budgets, facilitating rigorous post-marketing surveillance and effective risk management strategies. In juxtaposition, contract research organizations (CROs) are emerging players that cater specifically to the growing need for outsourced pharmacovigilance services, leveraging their specialized expertise to deliver tailored solutions for pharmaceutical and biotechnological enterprises. This collaboration between CROs and pharmaceutical firms allows for enhanced efficiency in safety monitoring, while CROs benefit from the robust demand for their services, particularly in clinical trial phases where monitoring is critical. As both entities evolve, their respective roles are pivotal in shaping the landscape of drug safety and regulatory compliance.

Get more detailed insights about India Pharmacovigilance Market
Request Free Sample

Key Players and Competitive Insights

The pharmacovigilance market in India is characterized by a dynamic competitive landscape, driven by increasing regulatory scrutiny and the growing emphasis on patient safety. Major players such as Parexel (US), Covance (US), and IQVIA (US) are strategically positioned to leverage their extensive experience and technological capabilities. Parexel (US) focuses on enhancing its data analytics capabilities, which appears to be a response to the rising demand for real-time safety monitoring. Covance (US), on the other hand, emphasizes its global reach and comprehensive service offerings, which likely enables it to cater to a diverse clientele effectively. Meanwhile, IQVIA (US) is investing heavily in digital transformation, suggesting a commitment to integrating advanced technologies into its pharmacovigilance processes. Collectively, these strategies indicate a trend towards innovation and operational efficiency, shaping a competitive environment that prioritizes quality and compliance.In terms of business tactics, companies are increasingly localizing their operations to better align with regional regulations and market needs. This localization strategy, coupled with supply chain optimization, is crucial in a market that is moderately fragmented, with several players vying for market share. The collective influence of these key players is significant, as they not only set industry standards but also drive advancements in pharmacovigilance practices across the region.

In October Parexel (US) announced a partnership with a leading Indian pharmaceutical company to enhance its pharmacovigilance services. This collaboration is expected to streamline data collection and reporting processes, thereby improving the overall efficiency of drug safety monitoring. Such strategic alliances are likely to bolster Parexel's market position by expanding its service capabilities and enhancing its local expertise.

In September Covance (US) launched a new AI-driven platform aimed at automating adverse event reporting. This initiative is particularly noteworthy as it reflects a broader trend towards the integration of artificial intelligence in pharmacovigilance. By automating routine tasks, Covance may significantly reduce the time and resources required for compliance, thereby enhancing its competitive edge in the market.

In August IQVIA (US) expanded its pharmacovigilance operations in India by establishing a new data analytics center. This move is indicative of the company's strategy to harness big data for improved safety monitoring and risk assessment. The establishment of this center not only enhances IQVIA's operational capabilities but also positions it as a leader in leveraging data analytics for pharmacovigilance.

As of November the competitive trends in the pharmacovigilance market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are playing a pivotal role in shaping the current landscape, enabling companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancement, and supply chain reliability. This shift suggests that companies that prioritize these elements are likely to thrive in an increasingly complex and regulated environment.

Key Companies in the India Pharmacovigilance Market include

Recent Industry Developments

Recent developments in the India Pharmacovigilance Market have been marked by increasing investments and technological advancements. Companies like Dr. Reddy's Laboratories and Zydus Cadila have been enhancing their pharmacovigilance systems, particularly with the integration of artificial intelligence and big data analytics to improve drug safety monitoring.

In September 2023, TCS and Cognizant emphasized the importance of digital transformation in pharmacovigilance, leading to better compliance and enhanced patient outcomes. Notably, in July 2023, Roche announced a collaboration with Clinipace to strengthen their pharmacovigilance frameworks in India, signaling a shift towards strategic partnerships in the market.

The market has seen robust growth, with a projected increase in valuations attributed to the amplified focus on patient safety and regulatory compliance. Additionally, companies such as Biocon and Wockhardt have reported positive impacts from regulatory changes promoting enhanced market standards.

In recent years, significant incidents, such as the implementation of new pharmacovigilance guidelines by the Indian government in February 2022, have driven the market's evolution, making India a crucial player in global pharmacovigilance strategies.

Future Outlook

India Pharmacovigilance Market Future Outlook

The Pharmacovigilance Market in India is projected to grow at 8.62% CAGR from 2025 to 2035, driven by regulatory advancements, technological innovations, and increasing patient safety awareness.

New opportunities lie in:

  • Development of AI-driven adverse event reporting systems
  • Expansion of real-time data analytics for drug safety
  • Partnerships with healthcare providers for integrated pharmacovigilance solutions

By 2035, the pharmacovigilance market is expected to be robust, driven by innovation and strategic collaborations.

Market Segmentation

India Pharmacovigilance Market Source Outlook

  • Spontaneous Reporting
  • Literature Reports
  • Scheduled Reporting

India Pharmacovigilance Market End User Outlook

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Research Organizations

India Pharmacovigilance Market Service Type Outlook

  • Adverse Event Reporting
  • Risk Assessment
  • Data Mining
  • Pharmacovigilance Consulting

India Pharmacovigilance Market Deployment Mode Outlook

  • Cloud-Based
  • On-Premise

Report Scope

MARKET SIZE 2024 314.13(USD Million)
MARKET SIZE 2025 341.21(USD Million)
MARKET SIZE 2035 780.04(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 8.62% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Parexel (US), Covance (US), IQVIA (US), Wuxi AppTec (CN), Syneos Health (US), Medpace (US), PPD (US), Charles River (US)
Segments Covered Service Type, Deployment Mode, Source, End User
Key Market Opportunities Integration of artificial intelligence in pharmacovigilance enhances drug safety monitoring and regulatory compliance.
Key Market Dynamics Growing regulatory scrutiny and technological advancements drive innovation in the pharmacovigilance market.
Countries Covered India

Frequently Asked Questions

What was the market valuation of the India pharmacovigilance market in 2024?

The market valuation was $314.13 Million in 2024.

What is the projected market valuation for the India pharmacovigilance market by 2035?

The projected valuation for 2035 is $780.04 Million.

What is the expected CAGR for the India pharmacovigilance market during the forecast period 2025 - 2035?

The expected CAGR during this period is 8.62%.

Which service type had the highest valuation in the India pharmacovigilance market in 2024?

Pharmacovigilance Consulting had the highest valuation at $104.13 Million in 2024.

What are the two main deployment modes in the India pharmacovigilance market?

The two main deployment modes are Cloud-Based and On-Premise.

What was the valuation range for Cloud-Based deployment mode in 2024?

The valuation range for Cloud-Based deployment mode was $150.0 Million to $380.0 Million.

Which end user segment had the highest valuation in 2024?

Pharmaceutical Companies had the highest valuation at $150.0 Million in 2024.

What is the valuation range for Scheduled Reporting in the India pharmacovigilance market?

The valuation range for Scheduled Reporting is $134.13 Million to $330.04 Million.

Who are some of the key players in the India pharmacovigilance market?

Key players include Parexel, Covance, IQVIA, and Wuxi AppTec.

What was the valuation for Risk Assessment services in 2024?

The valuation for Risk Assessment services was between $70.0 Million and $150.0 Million in 2024.

Author
Author Author Profile Nidhi Mandole LinkedIn Senior Research Analyst
She is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Nidhi is comfortably versed in data centric research backed by healthcare educational background. She leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. Her key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, she showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Co-Author Co-Author Profile Rahul Gotadki LinkedIn Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch
Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.